Stock GRF GRIFOLS, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
8.386 EUR +3.71% Intraday chart for Grifols, S.A. +0.48% -45.74%
Apr. 23 European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading MT
Apr. 23 Grifols to Launch EUR1 Billion Note Offering MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 18,760 14,161 9,783 6,557 9,231 5,070 - -
Enterprise Value (EV) 1 25,225 20,597 16,478 15,716 18,568 14,188 13,404 12,922
P/E ratio 34.5 x 26.5 x 62.5 x 34.7 x 172 x 10.7 x 7.53 x 6.27 x
Yield 1.15% 0.71% 2.13% - - - 2.85% 6.29%
Capitalization / Revenue 3.68 x 2.65 x 1.98 x 1.08 x 1.4 x 0.71 x 0.66 x 0.64 x
EV / Revenue 4.95 x 3.86 x 3.34 x 2.59 x 2.82 x 2 x 1.76 x 1.62 x
EV / EBITDA 17.9 x 13.9 x 17.1 x 12.9 x 12.8 x 7.69 x 6.32 x 5.73 x
EV / FCF 161 x 25.7 x 52.1 x -56.7 x -213 x 21.6 x 17.3 x -
FCF Yield 0.62% 3.9% 1.92% -1.76% -0.47% 4.63% 5.78% -
Price to Book 4.46 x 1.99 x 1.89 x 1.19 x 1.79 x 0.85 x 0.72 x 0.56 x
Nbr of stocks (in thousands) 684,135 684,540 682,484 678,911 678,665 679,092 - -
Reference price 2 31.43 23.88 16.88 10.77 15.46 8.386 8.386 8.386
Announcement Date 2/27/20 2/26/21 2/28/22 2/28/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,099 5,340 4,933 6,064 6,592 7,093 7,631 7,974
EBITDA 1 1,407 1,479 961.5 1,221 1,455 1,845 2,120 2,255
EBIT 1 1,131 996.1 595.1 805.7 1,023 1,346 1,589 1,658
Operating Margin 22.19% 18.65% 12.06% 13.29% 15.52% 18.97% 20.82% 20.79%
Earnings before Tax (EBT) 1 817.1 878.6 350.5 361.3 224 772.8 1,121 1,139
Net income 1 625.1 618.5 182.8 208.3 59.32 488.7 731.7 833.9
Net margin 12.26% 11.58% 3.71% 3.43% 0.9% 6.89% 9.59% 10.46%
EPS 2 0.9100 0.9000 0.2700 0.3100 0.0900 0.7860 1.114 1.337
Free Cash Flow 1 156.6 802.2 316.1 -277.4 -87.14 656.7 774.5 -
FCF margin 3.07% 15.02% 6.41% -4.57% -1.32% 9.26% 10.15% -
FCF Conversion (EBITDA) 11.13% 54.24% 32.87% - - 35.6% 36.53% -
FCF Conversion (Net income) 25.05% 129.7% 172.91% - - 134.37% 105.85% -
Dividend per Share 2 0.3600 0.1700 0.3600 - - - 0.2391 0.5275
Announcement Date 2/27/20 2/26/21 2/28/22 2/28/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 2,677 2,537 1,198 1,198 2,396 1,405 1,543 2,810 1,541 1,713 3,254 1,561 1,663 3,225 1,597 1,770 1,648 1,765 1,747 1,840
EBITDA 1 731.4 634.5 - - 327 248.2 - 618.3 308 294 602.7 298.8 360.7 659.5 373.6 426.3 381.5 459.4 456.1 -
EBIT 1 421.7 463.6 - - 131.5 - - 427.3 173.4 176.9 378.3 175.7 253.6 - 264.4 329.3 250.1 339.2 336 -
Operating Margin 15.75% 18.27% - - 5.49% - - 15.21% 11.25% 10.33% 11.63% 11.25% 15.25% - 16.55% 18.61% 15.18% 19.22% 19.23% -
Earnings before Tax (EBT) 1 - 378.2 - - -27.78 - - 227.9 66.69 46.88 133.4 -84.17 103.2 19.05 99.59 105.4 49.75 69.75 81.75 107.2
Net income 1 218.2 266.8 - - -84.01 - - 143.6 45 20.07 64.63 -108.3 52.04 -56.22 59.54 55.99 41.02 71.22 77.38 68.76
Net margin 8.15% 10.52% - - -3.51% - - 5.11% 2.92% 1.17% 1.99% -6.93% 3.13% -1.74% 3.73% 3.16% 2.49% 4.04% 4.43% 3.74%
EPS 2 - 0.3900 -0.0600 - -0.1200 - - 0.2100 - - 0.1000 - 0.0800 - - - 0.0748 0.1762 0.1725 0.0515
Dividend per Share - - - - - - - - - - - - - - - - - - - -
Announcement Date 7/30/20 7/29/21 2/28/22 2/28/22 2/28/22 7/28/22 7/28/22 7/28/22 11/8/22 2/28/23 2/28/23 5/9/23 7/27/23 7/27/23 11/2/23 2/28/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 6,465 6,436 6,695 9,158 9,337 9,118 8,334 7,852
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 4.595 x 4.352 x 6.963 x 7.501 x 6.419 x 4.942 x 3.931 x 3.482 x
Free Cash Flow 1 157 802 316 -277 -87.1 657 775 -
ROE (net income / shareholders' equity) 15.9% 12.5% 3.26% 3.57% 3.72% 9.02% 11.1% 11.6%
ROA (Net income/ Total Assets) 5.13% 4.01% 1.06% 1.02% 1.04% 2.15% 3.08% 3.07%
Assets 1 12,193 15,409 17,254 20,384 5,701 22,735 23,759 27,135
Book Value Per Share 2 7.050 12.00 8.950 9.040 8.640 9.920 11.70 14.80
Cash Flow per Share 2 0.8300 1.620 0.8800 -0.0200 0.3100 1.040 1.660 1.670
Capex 1 412 308 281 266 295 454 364 379
Capex / Sales 8.09% 5.77% 5.69% 4.39% 4.48% 6.4% 4.77% 4.75%
Announcement Date 2/27/20 2/26/21 2/28/22 2/28/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Grifols, S.A.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
8.386 EUR
Average target price
18.03 EUR
Spread / Average Target
+115.03%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
GRIFOLS, S.A. Stock Grifols, S.A.
-45.74% 5.41B
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. Financials Grifols, S.A.